sellWeak cluster of 2
Charles A. Deignan sold $17k of CLSD
Chief Financial Officer at Clearside Biomedical, Inc.. 12,900 shares at an average of $1.28, traded Jan 19, 2024, filed Jan 19, 2024.
Warning score
30Value
$17k
12,900 shares
Holdings after
384,662
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$17k at market
- 0Share of holdings soldSold 3.2% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-24-001959, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 19, 2024 | SOpen-market sale Common Stock | -12,900 | $1.28 | $17k | 384,662 | Jan 19, 2024 |
| Jan 18, 2024 | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 19, 2024 |
Related signals
Other insiders at Clearside Biomedical, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | CLSDbuy Clearside Biomedical, Inc. | Clay Thorp director | $14k 15,000 shares | +9% | |
| 31Weak | CLSDbuy Clearside Biomedical, Inc. | Ngai Hang Victor Chong Chief Medical Officer | $37k 36,500 shares | +57% | |
| 25Weak | CLSDbuy Clearside Biomedical, Inc. | Ngai Hang Victor Chong Chief Medical Officer | $25k 23,500 shares | +59% | |
| 30Weak | CLSDbuy Clearside Biomedical, Inc. | Ngai Hang Victor Chong CHIEF MEDICAL OFFICER | $48k 30,000 shares | - | |
| 24Weak | CLSDbuy Clearside Biomedical, Inc. | Bradford T Whitmore owner | $600k 444,444 shares | +11% | |
| 33Weak | Clearside Biomedical, Inc. | George M Lasezkay CEO | $23k 18,000 shares | -4% | |
| 12Weak | CLSDbuy Clearside Biomedical, Inc. | Bradford T Whitmore owner | $100k 135,778 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.